SCHEMBL4415367

SCHEMBL4415367

CC(C)(C)c1ccc(C(=O)N2CC3C(CNC(=O)c4[c]ccc(Cl)n4)C3C2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
ALOX15 P16050 1/20 0.37
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
NPY5R Q15761 2/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
LMNA P02545 2/20 0.36
THRB P10828 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415706 0.84 HPGD (0.44) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4418158 0.83 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4414867 0.83 GBA1 (0.36) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4413362 0.83 GAA (0.43) SMN1; SMN2ALDH1A1HTTPOLBRAB9A
SCHEMBL4419305 0.83 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL6500299 0.82 HPGD (0.34) CACNA1HSMN1; SMN2ALDH1A1MAPK1MEN1
SCHEMBL4550709 0.82 ADRA1A (0.36) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4414890 0.82 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2AALOX15
SCHEMBL4552442 0.81 MEN1 (0.34) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4421392 0.81 HPGD (0.41) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 CACNA1H 390/4885SMN1; SMN2 4003/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.